Comparative Pharmacology
Head-to-head clinical analysis: COLOCORT versus DEPO MEDROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COLOCORT versus DEPO MEDROL.
COLOCORT vs DEPO-MEDROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Colocort (hydrocortisone acetate) is a corticosteroid that binds to the glucocorticoid receptor, leading to inhibition of inflammatory mediators such as prostaglandins and leukotrienes, and suppression of immune responses.
Methylprednisolone acetate is a synthetic glucocorticoid receptor agonist that modulates gene expression to suppress inflammation, immune responses, and adrenal function by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and decreasing cytokine production.
10 mg rectally administered once daily, preferably at bedtime, as a retention enema.
IV: 10-40 mg every 1-2 weeks; IM: 40-120 mg every 1-4 weeks; Intra-articular/soft tissue: 4-80 mg per injection, repeat every 1-5 weeks as needed.
None Documented
None Documented
Terminal elimination half-life: 2.5–3.5 hours (mean ~3 hours). No active metabolites, so duration of action correlates with half-life.
Plasma terminal elimination half-life: 2.5-4.0 hours (methylprednisolone acetate formulation). Duration of adrenal suppression correlates with tissue esterase hydrolysis and prolonged tissue retention.
Renal: ~30% as metabolites; fecal/biliary: ~20% as metabolites; remainder metabolized with minimal unchanged drug excreted.
Primarily hepatic metabolism; renal excretion of metabolites (<10% unchanged). Fecal excretion is minor (<5%).
Category C
Category C
Corticosteroid
Corticosteroid